Overview
Cell and gene therapies (CGT) are transforming oncology by enabling targeted, personalized treatment approaches designed to address the underlying mechanisms of cancer. These therapies offer new possibilities for treating hematological malignancies, solid tumors, pediatric cancers, and rare cancers by modifying cells or genetic material to improve therapeutic outcomes.
Technological advances in CAR-T cell therapy, CRISPR/Cas9 gene editing, RNA therapeutics, and epigenome editing are expanding treatment options. Clinical development and regulatory approvals have also demonstrated these therapies’ growing role in cancer care. However, challenges involving tumor heterogeneity, treatment resistance, precise delivery, manufacturing standardization, and regulatory requirements continue to influence their development and adoption.
As the field evolves, advances in gene-editing technologies and strategic collaborations are creating opportunities to improve treatment precision and accelerate the development of next-generation cancer therapies. This whitepaper examines CGT technologies, challenges and opportunities, recent trials and approvals, market dynamics, and the key players shaping cell and gene therapy in oncology.
Key Insights You’ll Gain
How Stellarix Can Help
Stellarix supports life sciences organizations, from large pharma companies to emerging biotech developers, in building competitive positions in oncology cell and gene therapy. With expertise in IP consulting, regulatory and risk advisory, and value and cost intelligence, we map patent landscapes, assess regulatory pathways, and evaluate the cost drivers shaping therapy development to help industry players advance therapies that are scientifically differentiated and commercially sustainable.
